Brickell Biotech Inc (NASDAQ:BBI)

0.6477
BATS BZX Real-Time Price
As of 1:47pm ET
 -0.0205 / -3.07%
Today’s Change
0.47
Today|||52-Week Range
3.98
-56.82%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$35.4M

Company Description

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Contact Information

Brickell Biotech, Inc.
5777 Central Avenue
Boulder Colorado 80301
P:(720) 505-4755
Investor Relations:

Employees

Shareholders

Individual stakeholders4.26%
Other institutional3.97%
Mutual fund holders3.47%

Top Executives

Robert B. BrownChief Executive Officer & Director
Andrew D. SklawerChief Operating Officer & Secretary
R. Michael CarruthersChief Financial Officer
Deepak ChadhaChief Research & Development Officer
Nancy SerettaHead-Clinical Operations